Science & Enterprise subscription

Follow us on Twitter

  • Regulatory review of a drug to prevent allergic reactions to peanuts appears to be delayed by the shutdown of some… https://t.co/mSAKgI1Dry
    about 6 hours ago
  • New post on Science and Enterprise: Shutdown Delays FDA Peanut Allergy Drug Review https://t.co/vvspUdBnOM #Science #Business
    about 6 hours ago
  • Customized implants, produced on a 3-D printer and seeded with stem cells, are shown in tests with lab animals to… https://t.co/hc4xTlmSQq
    about 11 hours ago
  • New post on Science and Enterprise: 3-D Printed Implants Treat Spinal Cord Injury https://t.co/2ZiVpVvMIz #Science #Business
    about 11 hours ago
  • New contributed post on Science and Enterprise: https://t.co/z76z7xMWD3 Lighten The Load: Making Business Ownership Less Complex
    about 16 hours ago

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn
INSTAGRAM

Janssen Licensing Cancer Antibodies in $1.8B Deal

Llama

An affiliate of drug maker Janssen Pharmaceutical is licensing a synthetic antibody to treat blood-related cancers from a developer of antibodies based on the immune system of llamas. . . . → Read More: Janssen Licensing Cancer Antibodies in $1.8B Deal

Investing In Science And Tech – What You Need To Know

If you think that these are the best sectors for you to invest in right now, these following tips should help you get started. . . . → Read More: Investing In Science And Tech – What You Need To Know

What Are Ways To Invest Your Money?

Here are some of the best ways to invest your money and hopefully make a tidy bit of profit, . . . → Read More: What Are Ways To Invest Your Money?

RNA Therapeutics Company Raises $30M in First Venture Round

Kevin Weeks

A company spun-off from a university biochemistry lab is raising $30 million to fund discovery of treatments targeting RNA, genetic material instructing protein production in cells. . . . → Read More: RNA Therapeutics Company Raises $30M in First Venture Round

Trial Underway for Inhaled Heart Rhythm Drug, Developer Raises $42M

Heartbeat graphic

A clinical trial is underway testing an inhaled therapy to quickly treat irregular heart rhythms, in cases where the problems occur occasionally and often resolve on their own. . . . → Read More: Trial Underway for Inhaled Heart Rhythm Drug, Developer Raises $42M

Synthetic DNA Company Raising $70 Million in IPO

NASDAQ share price display

A 5 year-old enterprise developing synthetic DNA for medical and agricultural chemicals, as well as data storage, is raising $70 million in its initial public stock offering. . . . → Read More: Synthetic DNA Company Raising $70 Million in IPO

Gene Silencing Technology Licensed in $3.7B Deal

RNA strand illustration

Dicerna Pharmaceuticals, developing treatments for disease that silence genes by interfering with their RNA instructions, is licensing its technology to drug maker Eli Lilly and Co . . . → Read More: Gene Silencing Technology Licensed in $3.7B Deal

Start-Up Developing Immunometabolism Therapies, Gains $30M Funding

T-cells illustration

A start-up enterprise founded by medical researchers in the U.S. and Europe is developing treatments for cancer and autoimmune disorders that change chemical reactions in immune system cells. . . . → Read More: Start-Up Developing Immunometabolism Therapies, Gains $30M Funding

Biotech in $3.7B Licensing Deal for Hepatitis-B

Hepatitis-B virus

A biotechnology company developing therapies that silence the actions of disease-causing genes is licensing its treatment program for hepatitis-B to Janssen Pharmaceuticals. . . . → Read More: Biotech in $3.7B Licensing Deal for Hepatitis-B

$29.5M Funding Raised for Sinus Drug Delivery Company

Sinus doctor

A company developing a drug delivery technology to treat chronic sinus conditions is raising $29.5 million in its second venture financing round. . . . → Read More: $29.5M Funding Raised for Sinus Drug Delivery Company